---
title: "Dian Diagnostics: It is expected that AI business revenue will maintain a compound annual growth rate far exceeding 100% over the next three years"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/243623720.md"
description: "Dian Diagnostics expects its AI business revenue to maintain a compound annual growth rate of over 100% in the next three years. In 2024, AI-related business revenue is expected to be approximately 20 million yuan, primarily derived from the commercialization of AI pathology and other auxiliary diagnostic products. The company invests tens of millions of yuan annually in the AI field, focusing on data platforms, pathology AI, and health management. The AI business covers areas such as clinical decision support, health management, pharmaceutical services with AI+CRO, and data infrastructure"
datetime: "2025-06-09T02:56:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/243623720.md)
  - [en](https://longbridge.com/en/news/243623720.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/243623720.md)
generator: "portal-rs"
---

# Dian Diagnostics: It is expected that AI business revenue will maintain a compound annual growth rate far exceeding 100% over the next three years

Dian Diagnostics stated in an institutional research that the company's AI-related business revenue in 2024 is expected to be approximately 20 million yuan, mainly derived from the commercialization of AI pathology and other auxiliary diagnostic products and specialized disease database products. The company invests tens of millions of yuan annually in the AI field, focusing primarily on three core areas: data platforms, pathology AI, and health management. According to the three-year strategic plan, the AI business covers four directions: AI-driven clinical decision support, health management, AI + CRO services for pharmaceutical companies, and data foundation and regional "smart inspection linkage" business. It is expected that in the next three years, AI business revenue will maintain a compound annual growth rate far exceeding 100%

### Related Stocks

- [300244.CN](https://longbridge.com/en/quote/300244.CN.md)

## Related News & Research

- [LIVE MARKETS-Why the energy shock hasn't been so bad for Europe this time](https://longbridge.com/en/news/296100071.md)
- [UN candidate Baki vows focus on conflict prevention, UN renewal](https://longbridge.com/en/news/296525849.md)
- [Innventure directors force management, board to forfeit Accelsius earnout shares tied to DarkNX order](https://longbridge.com/en/news/296352522.md)
- [12:21 ETDoceree Launches Care Sequence, Activating One Clinical Signal Across All Moments of Care, From the Waiting Room to the Pharmacy Counter](https://longbridge.com/en/news/296517731.md)
- [China Shenhua unit Shendong Coal wins China invention patent for shearer fault diagnosis technology](https://longbridge.com/en/news/296561028.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**